175 related articles for article (PubMed ID: 38048694)
1. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
Schuster SJ; Huw LY; Bolen CR; Maximov V; Polson AG; Hatzi K; Lasater EA; Assouline SE; Bartlett NL; Budde LE; Matasar MJ; Koeppen H; Piccione EC; Wilson D; Wei MC; Yin S; Penuel E
Blood; 2024 Feb; 143(9):822-832. PubMed ID: 38048694
[TBL] [Abstract][Full Text] [Related]
2. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde LE; Assouline S; Sehn LH; Schuster SJ; Yoon SS; Yoon DH; Matasar MJ; Bosch F; Kim WS; Nastoupil LJ; Flinn IW; Shadman M; Diefenbach C; O'Hear C; Huang H; Kwan A; Li CC; Piccione EC; Wei MC; Yin S; Bartlett NL
J Clin Oncol; 2022 Feb; 40(5):481-491. PubMed ID: 34914545
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J; Fiaschi N; Deering RP; Cygan KJ; Scott D; Jeong S; Boucher L; Gupta NT; Gupta S; Adler C; Topp MS; Bannerji R; Duell J; Advani RH; Flink DM; Chaudhry A; Thurston G; Ambati SR; Jankovic V
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519055
[TBL] [Abstract][Full Text] [Related]
6. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
Liu X; Zhao J; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
8. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Bannerji R; Arnason JE; Advani RH; Brown JR; Allan JN; Ansell SM; Barnes JA; O'Brien SM; Chávez JC; Duell J; Rosenwald A; Crombie JL; Ufkin M; Li J; Zhu M; Ambati SR; Chaudhry A; Lowy I; Topp MS
Lancet Haematol; 2022 May; 9(5):e327-e339. PubMed ID: 35366963
[TBL] [Abstract][Full Text] [Related]
9. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
[TBL] [Abstract][Full Text] [Related]
10. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
11. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.
Matasar M; Bartlett NL; Shadman M; Budde LE; Flinn I; Gregory GP; Kim WS; Hess G; El-Sharkawi D; Diefenbach CS; Huang H; To I; Parreira J; Wu M; Kwan A; Assouline S
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):240-253. PubMed ID: 38195322
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P
Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543
[TBL] [Abstract][Full Text] [Related]
13. Mosunetuzumab: First Approval.
Kang C
Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
[TBL] [Abstract][Full Text] [Related]
14. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bartlett NL; Assouline S; Giri P; Schuster SJ; Cheah CY; Matasar M; Gregory GP; Yoon DH; Shadman M; Fay K; Yoon SS; Panizo C; Flinn I; Johnston A; Bosch F; Sehn LH; Wei MC; Yin S; To I; Li CC; Huang H; Kwan A; Penuel E; Budde LE
Blood Adv; 2023 Sep; 7(17):4926-4935. PubMed ID: 37067952
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial.
Buhmann R; Michael S; Juergen H; Horst L; Peschel C; Kolb HJ
J Transl Med; 2013 Jul; 11():160. PubMed ID: 23815981
[TBL] [Abstract][Full Text] [Related]
16. Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.
Matarasso S; Assouline S
Future Oncol; 2023 Oct; 19(31):2083-2101. PubMed ID: 37882361
[TBL] [Abstract][Full Text] [Related]
17. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Munakata W; Izutsu K; Mishima Y; Nagai H; Ishihara Y; Suzumiya J; Kanakura Y; Nanki T; Miyake T; Kawasaki A; Yoshinaga T; Ishizawa K
Jpn J Clin Oncol; 2023 Oct; 53(10):912-921. PubMed ID: 37486002
[TBL] [Abstract][Full Text] [Related]
19. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K
Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251
[TBL] [Abstract][Full Text] [Related]
20. The value of bispecific antibodies in relapsed and refractory DLBCL.
Lewis KL; Cheah CY
Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
